Oxford Gene Technology Ltd. Release: Pieces Of The Puzzle—A Multi-Method Approach To Tumour Profiling
Oxford, UK – 5 November 2014. Oxford Gene Technology (OGT), The Molecular Genetics Company, will present a workshop titled ‘An Integrated Genomic Approach to Tumor Profiling’ at the Association for Molecular Pathology (AMP) annual meeting on the 12-15th November at National Harbor, MD.
Research into the identification of clinically relevant genetic mutations is growing rapidly; however, the complexity of genomic variation means that the use of multiple technologies is often required to obtain a complete understanding of a given disease. James Clough, Executive Vice President Commercial, and Ephrem Chin, Business Development Manager at OGT, will explore how next generation sequencing (NGS), microarrays and fluorescence in situ hybridisation (FISH) can be combined to present a fully comprehensive, integrated approach and meet this growing need.
As NGS becomes more affordable, targeted sequencing provides an accurate, high-resolution approach to mutation detection. Developed in collaboration with recognised cancer experts, OGT’s SureSeq™ Solid Tumour Panel covers all exons of key genes for a range of cancer types including breast, prostate, ovarian, lung and colorectal – enabling detection and discovery of both known and novel variants. For detecting copy number variations (CNV), array comparative genomic hybridisation (aCGH) is still the gold standard, and OGT’s CytoSure Cancer +SNP Arrays also provide the facility to uncover LOH information. For certain aberrations such as translocations, however, FISH remains the most reliable mainstream technology, being the final piece of this genomic puzzle explored in OGT’s workshop.
Attendees of the workshop on November 12th, at 2pm in Maryland Ballroom C, will hear how the latest genomic technologies are being applied together to comprehensively characterise genetic abnormalities for accelerating cancer research.
Delegates can also find out more about OGT’s comprehensive molecular genetics solutions at booth 207 and enter a competition for the chance to win a SureSeq™ Solid Tumour Panel, or myProbes™ Custom FISH Probe project. For more information, please visit www.ogt.com.
For further information, please contact:
Oxford Gene Technology, Begbroke Science Park, Begbroke Hill, Woodstock Road, Begbroke, Oxfordshire, OX5 1PF, U.K.
T: +44 (0) 1865 856826 ; F: +44 (0) 1865 848684
E: contact@ogt.com ; W: www.ogt.com ; Twitter: @OxfordGeneTech
Notes for editors:
About Oxford Gene Technology
Oxford Gene Technology (OGT) provides world-class genetics research solutions to leading clinical and academic research institutions. Founded by Professor Sir Edwin Southern, and with customers in over 60 countries worldwide, OGT has a strong reputation and increasing share in the large and growing genomic medicine market. The Company’s Cytocell®, CytoSure™, SureSeq™ and Genefficiency™ range of fluorescence in situ hybridisation (FISH), microarray and next generation sequencing (NGS) products and services deliver high-quality genetic analysis, enabling accurate identification and confirmation of the causative variation underlying genetic disease.
For more information on the Company, please visit our website at www.ogt.com
CytoSure™, SureSeq™ and Genefficiency™ NGS browser/report: For Research Use Only; Not for Use in Diagnostic Procedures.
Some products may not be available in the US.
Help employers find you! Check out all the jobs and post your resume.
Research into the identification of clinically relevant genetic mutations is growing rapidly; however, the complexity of genomic variation means that the use of multiple technologies is often required to obtain a complete understanding of a given disease. James Clough, Executive Vice President Commercial, and Ephrem Chin, Business Development Manager at OGT, will explore how next generation sequencing (NGS), microarrays and fluorescence in situ hybridisation (FISH) can be combined to present a fully comprehensive, integrated approach and meet this growing need.
As NGS becomes more affordable, targeted sequencing provides an accurate, high-resolution approach to mutation detection. Developed in collaboration with recognised cancer experts, OGT’s SureSeq™ Solid Tumour Panel covers all exons of key genes for a range of cancer types including breast, prostate, ovarian, lung and colorectal – enabling detection and discovery of both known and novel variants. For detecting copy number variations (CNV), array comparative genomic hybridisation (aCGH) is still the gold standard, and OGT’s CytoSure Cancer +SNP Arrays also provide the facility to uncover LOH information. For certain aberrations such as translocations, however, FISH remains the most reliable mainstream technology, being the final piece of this genomic puzzle explored in OGT’s workshop.
Attendees of the workshop on November 12th, at 2pm in Maryland Ballroom C, will hear how the latest genomic technologies are being applied together to comprehensively characterise genetic abnormalities for accelerating cancer research.
Delegates can also find out more about OGT’s comprehensive molecular genetics solutions at booth 207 and enter a competition for the chance to win a SureSeq™ Solid Tumour Panel, or myProbes™ Custom FISH Probe project. For more information, please visit www.ogt.com.
For further information, please contact:
Oxford Gene Technology, Begbroke Science Park, Begbroke Hill, Woodstock Road, Begbroke, Oxfordshire, OX5 1PF, U.K.
T: +44 (0) 1865 856826 ; F: +44 (0) 1865 848684
E: contact@ogt.com ; W: www.ogt.com ; Twitter: @OxfordGeneTech
Notes for editors:
About Oxford Gene Technology
Oxford Gene Technology (OGT) provides world-class genetics research solutions to leading clinical and academic research institutions. Founded by Professor Sir Edwin Southern, and with customers in over 60 countries worldwide, OGT has a strong reputation and increasing share in the large and growing genomic medicine market. The Company’s Cytocell®, CytoSure™, SureSeq™ and Genefficiency™ range of fluorescence in situ hybridisation (FISH), microarray and next generation sequencing (NGS) products and services deliver high-quality genetic analysis, enabling accurate identification and confirmation of the causative variation underlying genetic disease.
For more information on the Company, please visit our website at www.ogt.com
CytoSure™, SureSeq™ and Genefficiency™ NGS browser/report: For Research Use Only; Not for Use in Diagnostic Procedures.
Some products may not be available in the US.
Help employers find you! Check out all the jobs and post your resume.